Core Viewpoint - Dongbao Biological reported a revenue of 369 million yuan and a net profit of 36.97 million yuan for the first half of 2025, demonstrating resilience in a complex market environment through strategic market exploration and cost reduction initiatives [1] Group 1: Market Strategy and Performance - The company focused on the collagen industry strategy, enhancing operational efficiency through refined management and organizational improvements [2] - Dongbao Biological initiated a stock repurchase plan, buying back 10.57 million shares, representing 1.78% of its total share capital, to enhance shareholder value and investor confidence [2] - The company achieved significant growth in its gelatin segment, particularly in the blood plasma gelatin market, and saw an increase in revenue from its hollow capsule products [2] Group 2: Product Development and Innovation - Key R&D projects made substantial progress, including improvements in anti-pilling levels for collagen used in cashmere textiles and advancements in low-endotoxin gelatin [3] - The company is advancing its collagen products for hair care and has initiated market connections for various modified gelatin applications [3] Group 3: Industry Outlook and Growth Potential - Despite short-term performance pressures, the company is well-positioned for long-term growth due to its comprehensive production capabilities, management advantages, and strong R&D platform [4] - The pharmaceutical excipients market, particularly for hollow capsules, is expected to expand due to policy support and technological innovations, benefiting leading companies like Dongbao Biological [4] - The growing health consciousness among consumers is driving demand for nutritional health products and beauty care, creating new opportunities for collagen applications [4] Group 4: Expanding Applications and Market Opportunities - The introduction of blood plasma gelatin is extending the company's applications into the medical field, with potential uses in various medical products and procedures [5] - The "Healthy China" initiative is fostering a supportive policy environment for the health industry, which is expected to enhance market demand for high-quality health products [5][6] - Dongbao Biological is positioned to benefit from the ongoing high-quality development in the health sector, leveraging its management, technology, and brand advantages [6]

东宝生物（300239）公告，公司"倍优免牌骨胶原蛋白维生素C粉"产品于近日完成国产保健食品注册工 作，并获得国家市场监督管理总局发放的国产保健食品注册证书。该产品具有有助于增强免疫力的保健 功能，注册号为国食健注G20250138，有效期至2030年4月29日。 ...